Pain Control in Colorectal Surgery: Liposomal Bupivacaine Block Versus Intravenous Lidociane

• Status: Completed
• Trial end date: 2021-07-20
• Target enrollment: 0
• Participant gender: All

Summary

To compare the analgesic impact of intravenous perioperative lidocaine infusion with preoperative liposomal bupivacaine TAP block in colorectal surgery. This is to be integrated into the standard ERAS protocol currently utilized at Carolinas Medical Center. Primary endpoints will be postoperative pain as measured by verbal rate scale (VRS), postoperative morphine equivalents utilized per day, and over 30 days. Secondary endpoints will include date of ambulation, return of bowel function (first flatus), tolerance of goal diet, incidence of post-operative nausea and vomiting during hospital stay, length of stay (hospital and PACU), post-operative morbidity (Clavien-Dindo, related to both anesthesia and surgery), cost of hospitalization (operative, PACU, postoperative stay, and total) and quality of life on follow up.

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Atrium Health
• Treatments: Bupivacaine; Lidocaine

Criteria

Inclusion Criteria:

• Age 18-75 years

• Elective laparoscopic colorectal surgery

• ASA I-III

Exclusion Criteria:

• Contraindication to Na Channel Blocker

• Chronic Opioid use

• Liver dysfunction

• Renal insufficiency

• Epilepsy

• Psychomotor retardation

• BMI >40

• Sleep Apnea

• Cardiac Rhythm Disorders

• Planned open or concomitant procedure